Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to Ezetimibe/Simvastatin vs Doubling Statin Dose After Coronary Event
2004-002345-12Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ezetimibe in hypercholesterolemia (2 arms), sponsored by Merck & Co. Primary endpoint: LDL-C level at 12 weeks. Started Dec 2004; status: completed.
02
Drugs
ezetimibe
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2004-002345-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002345-12.